S&P 500

5.431,60

-0,04%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

0RQE

Idorsia (0RQE)

Idorsia Ltd

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:LSE:0RQE

1

Data	Hora	Fonte	Título	Código	Companhia
13/06/2024	06:00	UK Regulatory	Idorsia holds its Annual General Meeting of Shareholders	LSE:0RQE	Idorsia Ltd
03/06/2024	02:00	UK Regulatory	New data with daridorexant to be presented at SLEEP 2024	LSE:0RQE	Idorsia Ltd
31/05/2024	02:00	UK Regulatory	Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024	LSE:0RQE	Idorsia Ltd
23/05/2024	02:00	UK Regulatory	Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders	LSE:0RQE	Idorsia Ltd
21/05/2024	02:00	UK Regulatory	Idorsia announces changes to Idorsia Executive Committee and Board of Directors	LSE:0RQE	Idorsia Ltd
21/05/2024	01:50	UK Regulatory	Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor	LSE:0RQE	Idorsia Ltd
21/05/2024	01:40	UK Regulatory	Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value	LSE:0RQE	Idorsia Ltd
14/05/2024	12:45	UK Regulatory	Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call	LSE:0RQE	Idorsia Ltd
06/05/2024	13:35	UK Regulatory	Bondholders approve amended terms of the 2024 convertible bonds	LSE:0RQE	Idorsia Ltd
01/05/2024	13:00	UK Regulatory	Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond	LSE:0RQE	Idorsia Ltd
26/04/2024	02:00	UK Regulatory	JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension	LSE:0RQE	Idorsia Ltd
23/04/2024	02:00	UK Regulatory	Idorsia publishes an invitation to a bondholder meeting	LSE:0RQE	Idorsia Ltd
17/04/2024	02:00	UK Regulatory	Idorsia publishes a Financial Status required for an upcoming bondholder meeting	LSE:0RQE	Idorsia Ltd
11/04/2024	02:00	UK Regulatory	Idorsia takes steps to address short-term liquidity needs	LSE:0RQE	Idorsia Ltd
22/03/2024	03:00	UK Regulatory	Idorsia thanks Guy Braunstein for his years of service as he retires	LSE:0RQE	Idorsia Ltd
20/03/2024	03:00	UK Regulatory	US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives	LSE:0RQE	Idorsia Ltd
18/03/2024	03:00	UK Regulatory	Idorsia and Viatris successfully close the transaction for the global research and development collaboration	LSE:0RQE	Idorsia Ltd
28/02/2024	03:00	UK Regulatory	Idorsia and Viatris enter into a significant global research and development collaboration	LSE:0RQE	Idorsia Ltd